1. Home
  2. IDT vs ERAS Comparison

IDT vs ERAS Comparison

Compare IDT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IDT Corporation Class B

IDT

IDT Corporation Class B

N/A

Current Price

$50.82

Market Cap

1.2B

ML Signal

N/A

Logo Erasca Inc.

ERAS

Erasca Inc.

N/A

Current Price

$15.39

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IDT
ERAS
Founded
1990
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
IDT
ERAS
Price
$50.82
$15.39
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$7.20
AVG Volume (30 Days)
106.9K
3.3M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
0.47%
N/A
EPS Growth
N/A
16.87
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.99
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$15.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$45.35
$1.01
52 Week High
$71.12
$16.00

Technical Indicators

Market Signals
Indicator
IDT
ERAS
Relative Strength Index (RSI) 57.57 74.61
Support Level $50.02 $1.46
Resistance Level $52.24 N/A
Average True Range (ATR) 1.09 0.92
MACD 0.17 0.05
Stochastic Oscillator 69.59 84.91

Price Performance

Historical Comparison
IDT
ERAS

About IDT IDT Corporation Class B

IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Share on Social Networks: